Navigation Links
ChemoCentryx Announces Pricing of Initial Public Offering
Date:2/8/2012

hemokine and chemoattractant systems in order to treat autoimmune diseases, inflammatory disorders and cancer. The chemokine system is a biological network that regulates inflammation via a collection of secreted chemokine molecules, or ligands, and their specific cell surface receptors. Based on its proprietary drug discovery and drug development platform, ChemoCentryx has generated multiple clinical and preclinical-stage programs, each targeting distinct chemokine and chemoattractant receptors with different small molecule compounds.

Certain statements in this press release may constitute "forward-looking statements". These statements are made on the basis of current expectations, forecasts and assumptions that involve risks and uncertainties, including, but not limited to, economic, competitive, governmental and technological factors outside of our control, that may cause our business, strategy or actual results to differ materially from those expressed or implied. We do not intend, and undertake no obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise.

 

 


'/>"/>
SOURCE ChemoCentryx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. ChemoCentryx Reports Clinical Efficacy for CCX354, a Novel CCR1 Inhibitor in a Phase II Study in Patients with Rheumatoid Arthritis
2. ChemoCentryx Initiates Phase II Clinical Trial for CCX168, a Novel Small Molecule C5aR Antagonist for the Treatment of Vasculitis
3. ChemoCentryx Reports Novel CCR2 Antagonist Significantly Improves Kidney Function and Hyperglycemia in Models of Type 2 Diabetes
4. ChemoCentryx Initiates Phase I Clinical Trial of CCX832, the First Small Molecule Inhibitor of ChemR23
5. ChemoCentryx to Present at the 29th Annual J.P. Morgan Healthcare Conference
6. ChemoCentryx Reports Positive Phase I Results for CCX168, a Novel C5aR Antagonist, at the Annual American College of Rheumatology Meeting (ACR)
7. ChemoCentryx Reports One-Year Results from PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Treating Patients with Crohns Disease at the United European Gastroenterology Federation (UEGW) Meeting
8. ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD)
9. ChemoCentryx Reports that Traficet-EN Maintains Remission in Crohns Disease at the Digestive Disease Week (DDW) 2010 Conference
10. ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases
11. ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... BOSTON , Jan. 15, 2014 Tegra Medical is ... Mark King as its new Chief Executive Officer.  Mark ... in which he has overseen the company,s four facilities in ... and Costa Rica.  Mr. King joined Tegra Medical in 2012 ...
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... report is available in its catalogue: ... Forecast – Worldwide Analysis ... Market Analysis Insulin ...
(Date:1/15/2014)... Mass. , Jan. 15, 2014  Zafgen, Inc., ... unmet needs of severely obese patients, today announced ... beloranib, a selective inhibitor of methionine aminopeptidase 2 ... severe form of genetic obesity.  These results showed ...
Breaking Medicine Technology:Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
... Oclaro, Inc. (NASDAQ: OCLR ), ... today outlined its complete line of fiber laser solutions ... a leading provider of diodes for industrial fiber laser ... operations, technology expertise and packaging technology to consistently deliver ...
... What:   Investigators from Northwestern ... 510(k) regulatory pathway—through which more than 90% of medical ... study is the most comprehensive survey to date about ... Devices and Radiological Health (CDRH) is currently weighing regulatory ...
Cached Medicine Technology:Oclaro Provides Complete Fiber Laser Diode Solutions Portfolio; Outlines Future Innovation and Technology Advancements 2Oclaro Provides Complete Fiber Laser Diode Solutions Portfolio; Outlines Future Innovation and Technology Advancements 3Findings From Largest Industry Assessment of 510(k) Process to be Released on May 24, 2011 2
(Date:7/9/2014)... signals active in almost all types of cancer sends ... may help fuel a tumour,s uncontrolled growth, new research ... London, identified a molecular trigger responsible for ratcheting up ... factory that makes the building blocks cancer cells need ... signalling pathway, called SREBP, controls the flow of messages ...
(Date:7/9/2014)... support cells and immune cells and the role ... development of diseases could open new therapeutic avenues ... conclusion of a review article by scientists from VIB ... . , Prof. Peter Carmeliet: "Consider the review article ... cells has been examined in minute detail for decades ...
(Date:7/9/2014)... users in Russia might contribute to HIV transmission ... by researchers from Boston University Schools of Medicine ... Pavlov State University, sought to discover the effect ... a cohort of HIV-positive people with lifetime of ... by police were more likely to share needlesincreasing ...
(Date:7/9/2014)... is available in French . ... 14 year old teens, including brain structure and function, personality, ... who will go on to develop binge drinking within the ... and other variables such as life events and a family ... drinking. Whether or not the child had had a ...
(Date:7/9/2014)... the world have been linked to an emerging ... the National Institute for Mathematical and Biological Synthesis ... contribute. , In a series of mathematical ... hemorrhage of internal organs in frogs, could cause ... they are exposed to the virus every few ...
Breaking Medicine News(10 mins):Health News:Signal may send cancer's cellular factories into overdrive 2Health News:Wake-up call for more research into cell metabolism 2Health News:BU researchers relate arrests with HIV risk environment 2Health News:What drives a child to abuse alcohol? 2Health News:Study predicts ranavirus as potential new culprit in amphibian extinctions 2
... 80 Million Dogs in U.S. Households - One in ... TV news story on canine cancer by Fox,42 News, ... at http://www.kptm.com ),has generated emotional, heartfelt response and ... new treatments for dogs with cancer,as well as the ...
... of Rutgers University is one of 10 2008 Pew ... Pew Charitable Trusts. Launched in 1991, the Pew Latin ... trained Latin American scientists who show potential for stimulating ... as well as fostering collaboration between scientists in Latin ...
... Group,Inc. (Nasdaq: NYER ) announced that its ... Pharmacy Service Agreement with East Boston,Neighborhood Health Center ... period effective October 6, 2008. Under terms of ... each prescription dispensed in,exchange for providing comprehensive Clinical ...
... Costs for ... India, WEST BEND, Wis., Nov. 12 Anthem ... a new international medical,tourism pilot product that will allow ... designated facilities in India.,Beginning in January 2009, Anthem will ...
... - A novel protein marker has been found that ... regenerate injured liver tissue has the potential for cell-replacement ... of Pennsylvania School of Medicine led by Linda Greenbaum, ... Gastroenterology, have demonstrated that cells expressing the marker can ...
... or President should have an independent health examination to ensure ... today. , Lord David Owen, a trained doctor and ... people are affected by the decisions of people in high ... general public to ensure that their decision making is not ...
Cached Medicine News:Health News:Nyer Medical Group, Inc. Announces Pharmacy Service Agreement with East Boston Neighborhood Health Center 2Health News:Anthem Blue Cross and Blue Shield Introduces International Medical Tourism Pilot Program 2Health News:Anthem Blue Cross and Blue Shield Introduces International Medical Tourism Pilot Program 3Health News:Stem cells with potential to regenerate injured liver tissue identified by Penn researchers 2Health News:World leaders must be more open about their health 2
... 450,000 people in,the United States die ... a defibrillation shock,quickly during an episode ... that passes, the chance of,survival decreases ... Association,and JCAHO recommend that AEDs be ...
... female urinary stress incontinence (SUI) with a ... (BioArc™ SP) or a transobturator (BioArc™ TO) ... system combining synthetic and biologic materials. It ... The BioArc utilizes a polypropylene mesh for ...
... technology marries with the well-researched ... sling, for exceptional resultsby design. ... and host, reduces the potential ... or erosion and provides secure ...
Meets the demanding requirements of most pelvic floor reconstructive procedures, and is highly resistant to suture pull-through, demonstrating long-term durability, and serves as a structural support...
Medicine Products: